Beam Therapeutics Inc. (BEAM)
29.40
0.00 (0.00%)
Upcoming Events
Latest Headlines
Form 4 Beam Therapeutics Inc. For: Jun 03 Filed by: MARAGANORE JOHN
June 5, 2026 4:05 PM - SEC Filing
Form 4 Beam Therapeutics Inc. For: Jun 03 Filed by: Shaw Christi
June 5, 2026 4:05 PM - SEC Filing
Form 4 Beam Therapeutics Inc. For: Jun 03 Filed by: Walsh Kathleen E
June 5, 2026 4:05 PM - SEC Filing
Form 4 Beam Therapeutics Inc. For: Jun 03 Filed by: Guindo Chirfi
June 5, 2026 4:05 PM - SEC Filing
Form 4 Beam Therapeutics Inc. For: Jun 03 Filed by: COOPER GRAHAM K
June 5, 2026 4:05 PM - SEC Filing
Form 4 Beam Therapeutics Inc. For: Jun 03 Filed by: Fishman Mark
June 5, 2026 4:05 PM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)
May 21, 2026 6:39 AM - StreetInsider
Beam Therapeutics presents BEAM-302 data at conference
May 18, 2026 4:00 PM - StreetInsider
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
May 18, 2026 4:00 PM - Globe NewsWire
H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)
May 14, 2026 6:48 AM - StreetInsider
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1
May 13, 2026 11:49 AM - PR NewsWire
Beam Therapeutics Inc (BEAM) PT Lowered to $39 at Bernstein SocGen Group
May 13, 2026 7:15 AM - StreetInsider
Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference
May 13, 2026 7:00 AM - Globe NewsWire
Beam Therapeutics to present sickle cell therapy data at EHA2026
May 12, 2026 9:30 AM - StreetInsider
Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA20
May 12, 2026 9:30 AM - Globe NewsWire
Form 10-Q Beam Therapeutics Inc. For: Mar 31
May 7, 2026 7:23 AM - SEC Filing
Form 8-K Beam Therapeutics Inc. For: May 07
May 7, 2026 7:06 AM - SEC Filing
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
May 7, 2026 7:00 AM - Globe NewsWire
Form SCHEDULE 13G Beam Therapeutics Inc. Filed by: VANGUARD CAPITAL MANAGEMENT LLC
April 29, 2026 4:58 PM - SEC Filing
Form ARS Beam Therapeutics Inc. For: Dec 31
April 17, 2026 4:15 PM - SEC Filing
Form DEFA14A Beam Therapeutics Inc.
April 17, 2026 4:11 PM - SEC Filing
Form DEF 14A Beam Therapeutics Inc. For: Jun 03
April 17, 2026 4:05 PM - SEC Filing
Form 144 Beam Therapeutics Inc. Filed by: Ho Carole
April 14, 2026 4:28 PM - SEC Filing
Form 4 Beam Therapeutics Inc. For: Apr 01 Filed by: Evans John M.
April 6, 2026 5:49 PM - SEC Filing
Form 4 Beam Therapeutics Inc. For: Apr 01 Filed by: Simon Amy
April 6, 2026 5:45 PM - SEC Filing
Form 4 Beam Therapeutics Inc. For: Apr 01 Filed by: Cavanagh Bethany J
April 6, 2026 5:40 PM - SEC Filing
Form 4 Beam Therapeutics Inc. For: Apr 01 Filed by: Bellon Christine
April 6, 2026 5:40 PM - SEC Filing
Form 4 Beam Therapeutics Inc. For: Apr 01 Filed by: Ciaramella Giuseppe
April 6, 2026 5:35 PM - SEC Filing
Jones Trading Assumes Beam Therapeutics Inc (BEAM) at Buy
April 6, 2026 4:15 PM - StreetInsider
Form 4 Beam Therapeutics Inc. For: Mar 31 Filed by: Bellon Christine
April 2, 2026 5:27 PM - SEC Filing
Form 4 Beam Therapeutics Inc. For: Mar 31 Filed by: Cavanagh Bethany J
April 2, 2026 5:22 PM - SEC Filing
Form 4 Beam Therapeutics Inc. For: Mar 31 Filed by: Simon Amy
April 2, 2026 5:17 PM - SEC Filing
Form 4 Beam Therapeutics Inc. For: Mar 31 Filed by: Emany Sravan Kumar
April 2, 2026 5:16 PM - SEC Filing
Form 4 Beam Therapeutics Inc. For: Mar 31 Filed by: Ciaramella Giuseppe
April 2, 2026 5:16 PM - SEC Filing
Form 4 Beam Therapeutics Inc. For: Mar 30 Filed by: Evans John M.
April 1, 2026 6:32 PM - SEC Filing
Beam Therapeutics publishes sickle cell therapy data in medical journal
April 1, 2026 5:12 PM - StreetInsider
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine
April 1, 2026 5:12 PM - Globe NewsWire
Form 144 Beam Therapeutics Inc. Filed by: Bellon Christine
March 31, 2026 4:35 PM - SEC Filing
Form 144 Beam Therapeutics Inc. Filed by: Ciaramella Giuseppe
March 31, 2026 4:30 PM - SEC Filing
Form 144 Beam Therapeutics Inc. Filed by: Simon Amy
March 31, 2026 4:23 PM - SEC Filing
Form 144 Beam Therapeutics Inc. Filed by: Evans John M.
March 31, 2026 4:20 PM - SEC Filing
Form 144 Beam Therapeutics Inc. Filed by: Evans John M.
March 31, 2026 4:19 PM - SEC Filing
Form 144 Beam Therapeutics Inc. Filed by: Evans John M.
March 30, 2026 5:29 PM - SEC Filing
This U.S. biotech stock is 'grossly undervalued', Bernstein says
March 27, 2026 1:00 PM - StreetInsider
Form SCHEDULE 13G/A Beam Therapeutics Inc. Filed by: VANGUARD GROUP INC
March 26, 2026 4:13 PM - SEC Filing
Bernstein on Beam Therapeutics Inc (BEAM): 'Strong data but stock sells off'
March 26, 2026 8:29 AM - StreetInsider
Beam Therapeutics Inc (BEAM) PT Raised to $68 at Citi
March 25, 2026 4:11 PM - StreetInsider
Beam Therapeutics Inc (BEAM) PT Raised to $47 at Leerink Partners
March 25, 2026 1:09 PM - StreetInsider
Clear Street on Beam Therapeutics Inc (BEAM): muted reaction is 'buying opportunity'
March 25, 2026 1:00 PM - StreetInsider
William Blair stays Outperform on Beam Therapeutics Inc (BEAM) after "decisive validation' of BEAM-302 profile
March 25, 2026 12:57 PM - StreetInsider
RBC on Beam Therapeutics Inc (BEAM): 'we view the data as incrementally positive'
March 25, 2026 11:48 AM - StreetInsider
Beam Therapeutics selects 60 mg dose for BEAM-302 pivotal trial
March 25, 2026 7:00 AM - StreetInsider
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development
March 25, 2026 7:00 AM - StreetInsider
Full Article List
